Company Ultimovacs ASA

Equities

ULTI

NO0010851603

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Oslo Bors Other stock markets 03:03:14 2024-04-26 am EDT			5-day change	1st Jan Change
6.99 ^NOK	+0.87%		-15.88%	-94.31%

Apr. 17	Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments	MT
Apr. 17	Transcript : Ultimovacs ASA - Special Call

Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacsâ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.

Number of employees: 26

Managers	Title	Age	Since
Carlos de Sousa CEO	Chief Executive Officer	66	20-05-31
Hans Vassgård Eid DFI	Director of Finance/CFO	57	-
Ingunn Hagen Westgaard CTO	Chief Tech/Sci/R&D Officer	-	-
Jens Bjørheim CTO	Chief Tech/Sci/R&D Officer	-	-
Gustav Gaudernack CTO	Chief Tech/Sci/R&D Officer	-	-
Øivind Foss CTO	Chief Tech/Sci/R&D Officer	-	-
Audun Tornes CTO	Chief Tech/Sci/R&D Officer	-	-
Anne Hovi Worsøe IRC	Investor Relations Contact	60	21-09-30
Mc Callion Orla LAW	General Counsel	-	21-09-30
Gudrun Trøite PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Jónas Einarsson CHM	Chairman	67	11-01-25
Henrik Schüssler BRD	Director/Board Member	61	14-12-31
Kari Grønås BRD	Director/Board Member	59	18-12-31
Haakon Stenrod BRD	Director/Board Member	44	20-11-10

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	34,406,061	23,730,397 ( 68.97 %)	0	68.97 %

Name	Equities	%	Valuation
Bjørn Rune Gjelsten 18.89 %	6,495,866	18.89 %	5 M kr
Wilhelmsen Family 5.177 %	1,780,575	5.177 %	1 M kr
Hagen Stein Erik Family 4.960 %	1,705,957	4.960 %	1 M kr
Radiumhospitalets Forskningsstiftelse 4.417 %	1,519,263	4.417 %	1 M kr
Inven2 AS 4.140 %	1,424,127	4.140 %	1 M kr
Langøya Invest AS 4.059 %	1,396,006	4.059 %	1 M kr
Folketrygdfondet 3.715 %	1,277,908	3.715 %	943 991 kr
Else Helene Sundt 2.808 %	965,802	2.808 %	713 438 kr
Christian Gruner Sundt 2.565 %	882,132	2.565 %	651 631 kr
Sundt AS 2.335 %	803,321	2.335 %	593 413 kr

Ultimovacs ASA

Ullernchausséen 64

0379, Oslo

+47 41 38 00 80

http://www.ultimovacs.com

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

6.93 NOK

Average target price

6.5 NOK

Spread / Average Target

-6.20%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ULTIMOVACS ASA	-94.31%	21.7M
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+45.26%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research